PLATFORMS

We use the very latest nucleic acid production technologies

with platforms that can seamlessly scale-up to meet your needs

Manufacturing process

We use our ExoREADY platform to produce fast and efficiently the suited quantities of clinical product and support your results analysis. We , purified mRNA and encapsulated mRNA, following GMP requirements.

 

We can produce toxicology lots when GMP-like conditions are required and phase I up to III clinical lots as well as commercial scale product.

    Our approach and expertise

    Our optimal ExoREADY process ensures high quality at high speed, both during DNA synthesis as well as RNA production.

    Starting from a cell-free working bank, we only need a few days to obtain the linear DNA template for mRNA production without fermentation, nor plasmid linearization.

    Afterwards, ExoREADY uses an optimized in-vitro transcription method to obviate the need for downstream dsRNA clearance. Our optimal process reduces the consumption of capping reagents without sacrificing capping yield and requires fewer purification steps while still guaranteeing high quality.

    For our RNA product manufacturing, Exothera uses the Nfinity equipment, which is already at its final scale during non-GMP manufacturing, speeding up considerably your product development.

    ExoREADY uses automated process step operations that are based on the principles of intensification and chaining. This means that production is consistent and can be adapted for multiple different purposes simply by re-programming the used equipment, ensuring a high-quality, high-speed production.

    Thanks to our optimal process, we are able to produce up to 5g purified RNA/day (up to 500k doses per day) for clinical manufacturing.

     

    Ntensify™ Midi

    Manufacturing process

    We use our ExoREADY platform to produce fast and efficiently the suited quantities of clinical product and support your results analysis. We , purified mRNA and encapsulated mRNA, following GMP requirements.

    We can produce toxicology lots when GMP-like conditions are required and phase I up to III clinical lots as well as commercial scale product.

      Our approach and expertise

      Our optimal ExoREADY process ensures high quality at high speed, both during DNA synthesis as well as RNA production.

      Starting from a cell-free working bank, we only need a few days to obtain the linear DNA template for mRNA production without fermentation, nor plasmid linearization.

      Afterwards, ExoREADY uses an optimized in-vitro transcription method to obviate the need for downstream dsRNA clearance. Our optimal process reduces the consumption of capping reagents without sacrificing capping yield and requires fewer purification steps while still guaranteeing high quality.

      For our RNA product manufacturing, Exothera uses the Nfinity equipment, which is already at its final scale during non-GMP manufacturing, speeding up considerably your product development.

      ExoREADY uses automated process step operations that are based on the principles of intensification and chaining. This means that production is consistent and can be adapted for multiple different purposes simply by re-programming the used equipment, ensuring a high-quality, high-speed production.

      Thanks to our optimal process, we are able to produce up to 5g purified RNA/day (up to 500k doses per day) for clinical manufacturing.

       

      Ntensify™ Midi